Search Results - "Guerci, Agnes"

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study by Rea, Delphine, Nicolini, Franck E., Tulliez, Michel, Guilhot, François, Guilhot, Joelle, Guerci-Bresler, Agnès, Gardembas, Martine, Coiteux, Valérie, Guillerm, Gaelle, Legros, Laurence, Etienne, Gabriel, Pignon, Jean-Michel, Villemagne, Bruno, Escoffre-Barbe, Martine, Ianotto, Jean-Christophe, Charbonnier, Aude, Johnson-Ansah, Hyacinthe, Noel, Marie-Pierre, Rousselot, Philippe, Mahon, François-Xavier

“…STOP second generation (2G)–tyrosine kinase inhibitor (TKI) is a multicenter observational study designed to evaluate 2G-TKI discontinuation in chronic myeloid…”
Get full text

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease by ROUSSELOT, Philippe, CHARBONNIER, Aude, ESCOFFRE-BARBE, Martine, GUERCI-BRESLER, Agnès, TULLIEZ, Michel, PROST, Stéphane, SPENTCHIAN, Marc, CAYUELA, Jean Michel, REIFFERS, Josy, CHOMEL, Jean Claude, TURHAN, Ali, GUILHOT, Joëlle, CONY-MAKHOUL, Pascale, GUILHOT, François, MAHON, François-Xavier, AGAPE, Philippe, NICOLINI, Franck E, VARET, Bruno, GARDEMBAS, Martine, ETIENNE, Gabriel, REA, Delphine, ROY, Lydia

“…More than half of patients with chronic-phase chronic myelogenous leukemia (CP-CML) in complete molecular response (CMR) experience molecular relapse after…”
Get full text

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients by Nicolini, Franck Emmanuel, Dulucq, Stéphanie, Boureau, Lisa, Cony-Makhoul, Pascale, Charbonnier, Aude, Escoffre-Barbe, Martine, Rigal-Huguet, Françoise, Coiteux, Valérie, Varet, Bruno, Dubruille, Viviane, Lenain, Pascal, Rousselot, Philippe, Rea, Delphine, Guerci-Bresler, Agnès, Legros, Laurence, Liu, Jixing, Gardembas, Martine, Ianotto, Jean-Christophe, Turlure, Pascal, Johnson-Ansah, Hyacinthe, Martiniuc, Juliana, Jardel, Henry, Joly, Bertrand, Zunic, Patricia, Henni, Tawfiq, Villemagne, Bruno, Berger, Marc G, Cayssials, Emilie, Guilhot, François, Larosa, Fabrice, Guilhot, Joëlle, Etienne, Gabriel, Mahon, François-Xavier

“…Tyrosine kinase inhibitor (TKI) discontinuation is an emerging goal in chronic myelogenous leukemia (CML) management and several studies have demonstrated the…”
Get full text

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study by Rea, Delphine, Henry, Guylaine, Khaznadar, Zena, Etienne, Gabriel, Guilhot, François, Nicolini, Franck, Guilhot, Joelle, Rousselot, Philippe, Huguet, Françoise, Legros, Laurence, Gardembas, Martine, Dubruille, Viviane, Guerci-Bresler, Agnès, Charbonnier, Aude, Maloisel, Frédéric, Ianotto, Jean-Christophe, Villemagne, Bruno, Mahon, François-Xavier, Moins-Teisserenc, Hélène, Dulphy, Nicolas, Toubert, Antoine

“…Despite persistence of leukemic stem cells, patients with chronic myeloid leukemia who achieve and maintain deep molecular responses may successfully stop the…”
Get full text

Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia by Legros, Laurence, Nicolini, Franck E., Etienne, Gabriel, Rousselot, Philippe, Rea, Delphine, Giraudier, Stéphane, Guerci‐Bresler, Agnès, Huguet, Françoise, Gardembas, Martine, Escoffre, Martine, Ianotto, Jean‐Christophe, Noël, Marie‐Pierre, Varet, Bruno R., Pagliardini, Thomas, Touitou, Irit, Morisset, Stéphane, Mahon, Francois‐Xavier

“…BACKGROUND Several studies have demonstrated that approximately one‐half of patients with chronic myeloid leukemia (CML) who receive treatment with tyrosine…”
Get full text

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial by Lipton, Jeffrey H, Prof, Chuah, Charles, MD, Guerci-Bresler, Agnès, MD, Rosti, Gianantonio, Prof, Simpson, David, Prof, Assouline, Sarit, MD, Etienne, Gabriel, MD, Nicolini, Franck E, MD, le Coutre, Philipp, Prof, Clark, Richard E, Prof, Stenke, Leif, MD, Andorsky, David, MD, Oehler, Vivian, MD, Lustgarten, Stephanie, PhD, Rivera, Victor M, PhD, Clackson, Timothy, PhD, Haluska, Frank G, MD, Baccarani, Michele, Prof, Cortes, Jorge E, Prof, Guilhot, François, Prof, Hochhaus, Andreas, Prof, Hughes, Timothy, Prof, Kantarjian, Hagop M, Prof, Shah, Neil P, Prof, Talpaz, Moshe, Prof, Deininger, Michael W, Prof

“…Summary Background Ponatinib has shown potent activity against chronic myeloid leukaemia that is resistant to available treatment, although it is associated…”
Get full text

Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34− and immature CD34+ cells by Berger, Marc G., Lebecque, Benjamin, Tassin, Thomas, Dannus, Louis-Thomas, Berger, Juliette, Soucal, Mélanie, Guerci, Agnès, Cony-Makhoul, Pascale, Johnson, Hyacinthe, Etienne, Gabriel, Guyotat, Denis, Gagnieu, Marie-Claude, Pereira, Bruno, Saugues, Sandrine, Tournilhac, Olivier, Hermet, Eric, Bourgne, Céline

“…Accumulation in target cells is an essential pharmacokinetic step of targeted therapies. Tyrosine Kinase Inhibitors (TKI) against the BCR-ABL fusion protein in…”
Get full text

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial by Guilhot, Francois, Rigal-Huguet, Françoise, Guilhot, Joëlle, Guerci-Bresler, Agnès-Paule, Maloisel, Frédéric, Rea, Delphine, Coiteux, Valérie, Gardembas, Martine, Berthou, Christian, Vekhoff, Anne, Jourdan, Eric, Berger, Marc, Fouillard, Loïc, Alexis, Magda, Legros, Laurence, Rousselot, Philippe, Delmer, Alain, Lenain, Pascal, Escoffre Barbe, Martine, Gyan, Emmanuel, Bulabois, Claude-Eric, Dubruille, Viviane, Joly, Bertrand, Pollet, Bertrand, Cony-Makhoul, Pascale, Johnson-Ansah, Hyacinthe, Mercier, Melanie, Caillot, Denis, Charbonnier, Aude, Kiladjian, Jean-Jacques, Chapiro, Jacques, Penot, Amélie, Dorvaux, Véronique, Vaida, Iona, Santagostino, Alberto, Roy, Lydia, Zerazhi, Hacene, Deconinck, Eric, Maisonneuve, Herve, Plantier, Isabelle, Lebon, Delphine, Arkam, Yazid, Cambier, Nathalie, Ghomari, Kamel, Miclea, Jean-Michel, Glaisner, Sylvie, Cayuela, Jean-Michel, Chomel, Jean-Claude, Muller, Marc, Lhermitte, Ludovic, Delord, Marc, Preudhomme, Claude, Etienne, Gabriel, Mahon, François-Xavier, Nicolini, Franck- Emmanuel

“…The STI571 prospective randomised trial (SPIRIT) French trial is a four-arm study comparing imatinib (IM) 400 mg versus IM 600 mg, IM 400 mg + cytarabine…”
Get full text

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations by Adès, Lionel, Duployez, Nicolas, Guerci‐Bresler, Agnes, Laribi, Kamel, Peterlin, Pierre, Vey, Norbert, Thepot, Sylvain, Wickenhauser, Stefan, Zerazhi, Hacene, Stamatoullas, Aspassia, Wattel, Eric, Recher, Christian, Toma, Andrea, Dimicoli‐Salazar, Sophie, Braun, Thorsten, Beyne‐Rauzy, Odile, Marolleau, Jean‐Pierre, Cheze, Stéphane, Park, Sophie, Cluzeau, Thomas, Nimubona, Stanislas, Bordessoule, Dominique, Benramdane, Riad, Quesnel, Bruno, Amé, Shanti, Botton, Stéphane, Chermat, Fathia, Preudhomme, Claude, Chevret, Sylvie, Fenaux, Pierre

“…In order to improve the outcome observed with azacitidine (AZA) in higher‐risk Myelodysplastic syndrome (MDS), its combination with other drugs in MDS must be…”
Get full text

Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome by de Montalembert, Mariane, Ribeil, Jean-Antoine, Brousse, Valentine, Guerci-Bresler, Agnes, Stamatoullas, Aspasia, Vannier, Jean-Pierre, Dumesnil, Cécile, Lahary, Agnès, Touati, Mohamed, Bouabdallah, Krimo, Cavazzana, Marina, Chauzit, Emmanuelle, Baptiste, Amandine, Lefebvre, Thibaud, Puy, Hervé, Elie, Caroline, Karim, Zoubida, Ernst, Olivier, Rose, Christian

“…The risk and clinical significance of cardiac iron overload due to chronic transfusion varies with the underlying disease. Cardiac iron overload shortens the…”
Get full text

Cause of death and excess mortality in patients with lower‐risk myelodysplastic syndromes (MDS): A report from the European MDS registry by Mądry, Krzysztof, Lis, Karol, Fenaux, Pierre, Bowen, David, Symeonidis, Argiris, Mittelman, Moshe, Stauder, Reinhard, Čermák, Jaroslav, Sanz, Guillermo, Hellström‐Lindberg, Eva, Langemeijer, Saskia, Malcovati, Luca, Germing, Ulrich, Holm, Mette Skov, Guerci‐Bresler, Agnes, Culligan, Dominic, Sanhes, Laurence, Kotsianidis, Ioannis, Marrewijk, Corine, Crouch, Simon, Witte, Theo, Smith, Alex

“…Summary Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower‐risk MDS (LR‐MDS) is…”
Get full text

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group by Adès, Lionel, Thomas, Xavier, Guerci Bresler, Agnes, Raffoux, Emmanuel, Spertini, Olivier, Vey, Norbert, Marchand, Tony, Récher, Christian, Pigneux, Arnaud, Girault, Stephane, Deconinck, Eric, Gardin, Claude, Tournilhac, Olivier, Lambert, Jean Francois, Chevallier, Patrice, de Botton, Stephane, Lejeune, Juile, Dombret, Hervé, Chevret, Sylvie, Fenaux, Pierre

“…In standard risk acute promyelocytic leukemia, recent results have shown that ATRA + Arsenic trioxide combinations were at least as effective as classical ATRA…”
Get full text

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial by Dulucq, Stéphanie, Nicolini, Franck E, Rea, Delphine, Cony-Makhoul, Pascale, Charbonnier, Aude, Escoffre-Barbe, Martine, Coiteux, Valérie, Lenain, Pascal, Rigal-Huguet, Françoise, Liu, Jixing, Guerci-Bresler, Agnès, Legros, Laurence, Ianotto, Jean-Christophe, Gardembas, Martine, Turlure, Pascal, Dubruille, Viviane, Rousselot, Philippe, Martiniuc, Juliana, Jardel, Henry, Johnson-Ansah, Hyacinthe, Joly, Bertrand, Henni, Tawfiq, Cayssials, Emilie, Zunic, Patricia, Berger, Marc G, Villemagne, Bruno, Robbesyn, Fanny, Morisset, Stephane, Mahon, François-Xavier, Etienne, Gabriel

“…Discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia is feasible in clinical practice based on recently published…”
Get full text

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? by Kosmider, Olivier, Passet, Marie, Santini, Valeria, Platzbecker, Uwe, Andrieu, Valérie, Zini, Gina, Beyne-Rauzy, Odile, Guerci, Agnès, Masala, Erico, Balleari, Enrico, Bulycheva, Ekaterina, Dreyfus, François, Fenaux, Pierre, Fontenay, Michaela, Park, Sophie

Get full text

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation by Chomel, Jean Claude, Bonnet, Marie-Laure, Sorel, Nathalie, Sloma, Ivan, Bennaceur-Griscelli, Annelise, Rea, Delphine, Legros, Laurence, Marfaing-Koka, Anne, Bourhis, Jean-Henri, Ame, Shanti, Guerci-Bresler, Agnès, Rousselot, Philippe, Turhan, Ali G

“…During the last decade, the use of tyrosine kinase inhibitor (TKI) therapy has modified the natural history of chronic myeloid leukemia (CML) allowing an…”
Get full text

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM by Rose, Christian, Brechignac, Sabine, Vassilief, Dominique, Pascal, Laurent, Stamatoullas, Aspasia, Guerci, Agnes, Larbaa, Dalila, Dreyfus, François, Beyne-Rauzy, Odile, Chaury, Marie Pierre, Roy, Lydie, Cheze, Stephane, Morel, Pierre, Fenaux, Pierre

“…Abstract Background Iron chelation therapy (CT) improves survival in thalassemia major but its beneficial effects on survival in MDS patients remain uncertain…”
Get full text

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up by Cortes, Jorge E., Kantarjian, Hagop M., Rea, Delphine, Wetzler, Meir, Lipton, Jeffrey H., Akard, Luke, Khoury, H. Jean, Michallet, Mauricette, Guerci‐Bresler, Agnès, Chuah, Charles, Hellmann, Andrzej, Digumarti, Raghunadharao, Parikh, Purvish M., Legros, Laurence, Warzocha, Krzysztof, Baccarani, Michele, Li, Elizabeth, Munteanu, Mihaela, Nicolini, Franck E.

“…BACKGROUND Omacetaxine, a protein synthesis inhibitor, is indicated in the United States for the treatment of patients with chronic‐phase (CP) or…”
Get full text

Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML) by Gentil, Melanie, Hugues, Patricia, Desterke, Christophe, Telliam, Gladys, Sloma, Ivan, Souza, Lucas E B, Baykal, Seda, Artus, Jerome, Griscelli, Frank, Guerci, Agnes, Johnson-Ansah, Hyacinthe, Foudi, Adlen, Bennaceur-Griscelli, Annelise, Turhan, Ali G

“…Aryl Hydrocarbon Receptor (AHR) is an ubiquitous basic helix-loop-helix transcription factor, which is ligand-activated and involved in numerous biological…”
Get full text

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients by Thépot, Sylvain, Itzykson, Raphael, Seegers, Valerie, Recher, Christian, Raffoux, Emmanuel, Quesnel, Bruno, Delaunay, Jacques, Cluzeau, Thomas, Marfaing Koka, Anne, Stamatoullas, Aspasia, Chaury, Marie‐Pierre, Dartigeas, Caroline, Cheze, Stéphane, Banos, Anne, Morel, Pierre, Plantier, Isabelle, Taksin, Anne‐Laure, Marolleau, Jean Pierre, Pautas, Cecile, Thomas, Xavier, Isnard, Francoise, Beve, Blandine, Chait, Yasmine, Guerci, Agnes, Vey, Norbert, Dreyfus, Francois, Ades, Lionel, Ifrah, Norbert, Dombret, Herve, Fenaux, Pierre, Gardin, Claude

“…Limited data are available on azacitidine (AZA) treatment and its prognostic factors in acute myeloid leukemia (AML). One hundred and forty‐nine previously…”
Get full text

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial) by Rahmé, Ramy, Ades, Lionel, Thomas, Xavier, Guerci-Bresler, Agnès, Pigneux, Arnaud, Vey, Norbert, Raffoux, Emmanuel, Castaigne, Sylvie, Spertini, Olivier, Wittnebel, Sebastian, Marolleau, Jean Pierre, Damaj, Gandhi, Bordessoule, Dominique, Lejeune, Julie, Chevret, Sylvie, Fenaux, Pierre

Get full text